High tumor mutation burden mitigates the negative impact of chemotherapy history on immune checkpoint blockade therapy. Zheng M. Semin Oncol 2025;52:152334.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zheng M. High tumor mutation burden mitigates the negative impact of chemotherapy history on immune checkpoint blockade therapy. Semin Oncol 2025;52:152334.
PMID: 40081267